NCT06863961

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of RO7790121 in Patients With Moderate to Severe Atopic Dermatitis

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 160 (estimated)
• Sponsor: Hoffmann-La Roche · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic dermatitis (AD).

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	Afimkibart	Afimkibart will be administered as SC injection.
DRUG	Placebo	Placebo will be administered as SC injection.

Timeline

• Start date: 2025-04-01
• Primary completion: 2026-10-05
• Completion: 2027-04-19
• First posted: 2025-03-07
• Last updated: 2026-04-08

Locations

69 sites across 8 countries: United States, Brazil, Canada, France, Germany, Italy, Poland, Spain

Regulatory

• FDA-regulated drug study